Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2014

View Archived Issues

Whole-exome sequencing links motor neuron disease and neurodegenerative disorders

Zenith Epigenetics identifies new compounds for epigenetics drug discovery

Catalyst Biosciences presents new polypeptides for coagulation disorders

FDA grants orphan drug status to "lost" drug for AML

Prana Biotechnology reports phase II results in Huntington's disease trial

Researchers at Biogen Idec prepare novel autotaxin inhibitors

Elite Pharmaceuticals reports data from pilot bioequivalence study of ELI-201

Supplemental NDA for Lymphoseek granted priority review by FDA

New seriniquinone derivatives with utility for cancer

Servier Canada invests in two research projects supported by Quebec government

French group discloses novel CYP26A1 inhibitors for dermatological disorders

RaQualia Pharma collaborates with Nagoya University

Millennium Pharmaceuticals synthesizes new UBA6 inhibitors for cancer

CNB-001 demonstrates promising neuroprotective activity in vivo

Genfit's GFT-505 granted FDA fast track designation

Boehringer Ingelheim divulges novel PDE2A inhibitors

Dynavax withdraws European marketing application for Heplisav

Japanese researchers design new delta opioid receptor agonists

Vital Therapies enrolls first subject in Europe in VTI-208 study

DNA hypermethylation associated with shortened PFS in patients with RCC

Second phase Ib trial of OMP-54F28 with Nexavar in HCC begins

International Stem Cell Corp. and FDA hold pre-IND meeting for Parkinson's disease cell therapy

FDA grants accelerated approval to Northera in symptomatic NOH

Eleven Biotherapeutics begins pivotal phase III study of EBI-005

FDA approves California Stem Cell's phase II stem trial for ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...